| From: |
|
Alison Bunce - Medicines and Healthcare Products Regulatory Agency
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Trusts (England) - Medical Director
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
|
|
|
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Chief Executive
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Title: |
|
DRUG ALERT CLASS 1, IMMEDIATE ACTION, DEXCEL PHARMA LIMITED, VALSARTAN 40MG, 80MG and 160MG CAPSULES; ACTAVIS GROUP PTC EHF, VALSARTAN 40MG, 80MG, 160MG AND 320MG FILM COATED TABLETS
|
| Broadcast content: |
|
All batches of the above are being recalled at a European level as a precautionary measure due to possible contamination with an impurity, N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.
Full details of the drug alert are included in the attached PDF file. PLease forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts
|
| Cascade to: |
|
- #GP#
- #COMMUNITYPHARMACISTS#
- #HospitalPharmacy#
|